Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 869-872

  Bernabeu, Ignacio ^a   Cameselle Teijeiro, Jose ^a   Casanueva, Felipe F ^a,b   Marazuela, Monica ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ATORVASTATIN; CABERGOLINE; ESTRADIOL PLUS NORETHISTERONE ACETATE; LEVOTHYROXINE; OCTREOTIDE; PARACETAMOL; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CHOLESTATIC HEPATITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GILBERT DISEASE; HEADACHE; HORMONE DEFICIENCY; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPOPHYSIS ADENOMA; JAUNDICE; LIVER BIOPSY; LIVER FUNCTION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RADIATION; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; INTRAHEPATIC CHOLESTASIS; OBSTRUCTIVE JAUNDICE; SYNDROME;

ACROMEGALY; ADULT; CHOLESTASIS, INTRAHEPATIC; FEMALE; GILBERT DISEASE; HUMAN GROWTH HORMONE; HUMANS; JAUNDICE, OBSTRUCTIVE; SYNDROME;

EID: 65549102025     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0040     Document Type: Article

References (18)

1. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
2. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
3. Hodish I & Barkan A. Long-term effects of pegvisomant in patients with acromegaly. Nature Clinical Practice. Endocrinology and Metabolism 2008 4 324-332.
4. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H & Strasburger CJ. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006 154 213-220.
5. Kaplowitz N. Drug-induced liver injury. Clinical Infectious Diseases 2004 38 S44-S48.
6. Chowdhury N, Wang X, Chowdhury JR, Kaplan MM & Bonis P. Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction. In UpToDate, Ed. DS Basow, Waltham, MA: UpToDate, 2008.
7. Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramirez M, Halperin I, Casanueva FF & Bernabeu I. Long-term treatment of acromegalic patients resistant to somatostatin analogs with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European Journal of Endocrinology 2009 160 535-542.
8. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF1 levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
9. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
10. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
11. Feenstra J, van Aken MO, de Herder WW, Feelders RA & van der Lely AJ. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology 2006 154 805-806.
12. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
13. Paisley AN, Roberts ME & Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clinical Endocrinology 2007 66 723-726.
14. Paisley A & Trainer P. Is withdrawal of somatostatin analogue therapy in patients with acromegaly associated with an increased risk of acute biliary problems? Clinical Endocrinology 2008 68 153-154.
15. Tranter SE & Thompson MH. Spontaneous passage of bile duct stones: frequency of occurrence and relation to clinical presentation. Annals of the Royal College of Surgeons of England 2003 85 174-177.
16. Portincasa P, Moschetta A, Petruzzelli M, Palasciano G, Di Ciaula A & Pezzolla A. Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Practice & Research. Clinical Gastroenterology 2006 20 1017-1029.
17. Freitas ML, Bell RL & Duffy AJ. Choledocholithiasis: evolving standards for diagnosis and management. World Journal of Gastroenterology 2006 12 3162-3167.
18. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D & Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicology Letters 2000 112-113 333-340.